Correlation
The correlation between VRNA and CELH is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
VRNA vs. CELH
Compare and contrast key facts about Verona Pharma plc (VRNA) and Celsius Holdings, Inc. (CELH).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: VRNA or CELH.
Performance
VRNA vs. CELH - Performance Comparison
Loading data...
Key characteristics
VRNA:
9.39
CELH:
-0.83
VRNA:
6.28
CELH:
-1.65
VRNA:
1.78
CELH:
0.82
VRNA:
9.70
CELH:
-0.79
VRNA:
87.86
CELH:
-1.07
VRNA:
6.19%
CELH:
57.68%
VRNA:
60.16%
CELH:
66.02%
VRNA:
-89.71%
CELH:
-99.79%
VRNA:
0.00%
CELH:
-62.19%
Fundamentals
VRNA:
$6.28B
CELH:
$9.55B
VRNA:
-$2.00
CELH:
$0.33
VRNA:
0.00
CELH:
1.18
VRNA:
53.00
CELH:
7.18
VRNA:
27.78
CELH:
21.54
VRNA:
$118.54M
CELH:
$1.33B
VRNA:
$112.28M
CELH:
$670.37M
VRNA:
-$176.07M
CELH:
$133.23M
Returns By Period
In the year-to-date period, VRNA achieves a 66.86% return, which is significantly higher than CELH's 37.97% return.
VRNA
66.86%
5.84%
94.21%
553.92%
158.62%
74.71%
N/A
CELH
37.97%
2.48%
28.09%
-54.47%
15.44%
63.71%
46.52%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
VRNA vs. CELH — Risk-Adjusted Performance Rank
VRNA
CELH
VRNA vs. CELH - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Celsius Holdings, Inc. (CELH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
VRNA vs. CELH - Dividend Comparison
Neither VRNA nor CELH has paid dividends to shareholders.
Drawdowns
VRNA vs. CELH - Drawdown Comparison
The maximum VRNA drawdown since its inception was -89.71%, smaller than the maximum CELH drawdown of -99.79%. Use the drawdown chart below to compare losses from any high point for VRNA and CELH.
Loading data...
Volatility
VRNA vs. CELH - Volatility Comparison
Verona Pharma plc (VRNA) and Celsius Holdings, Inc. (CELH) have volatilities of 13.16% and 13.33%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
VRNA vs. CELH - Financials Comparison
This section allows you to compare key financial metrics between Verona Pharma plc and Celsius Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
VRNA vs. CELH - Profitability Comparison
VRNA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Verona Pharma plc reported a gross profit of 72.85M and revenue of 76.26M. Therefore, the gross margin over that period was 95.5%.
CELH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Celsius Holdings, Inc. reported a gross profit of 172.37M and revenue of 329.28M. Therefore, the gross margin over that period was 52.4%.
VRNA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Verona Pharma plc reported an operating income of -10.32M and revenue of 76.26M, resulting in an operating margin of -13.5%.
CELH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Celsius Holdings, Inc. reported an operating income of 52.03M and revenue of 329.28M, resulting in an operating margin of 15.8%.
VRNA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Verona Pharma plc reported a net income of -16.32M and revenue of 76.26M, resulting in a net margin of -21.4%.
CELH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Celsius Holdings, Inc. reported a net income of 77.57M and revenue of 329.28M, resulting in a net margin of 23.6%.